About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
Article Date
April 9, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
August 13, 2026
The Oligodendrocyte Advantage
August 13, 2026
The Oligodendrocyte Advantage
June 17, 2026
BioHub podcast with Sean A. MacDonald, CEO at Kainova Therapeutics
June 17, 2026
BioHub podcast with Sean A. MacDonald, CEO at Kainova Therapeutics
